针对一种异源、非诱导合胞体的原发性人类免疫缺陷病毒的疫苗保护作用。
Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus.
作者信息
Robert-Guroff M, Kaur H, Patterson L J, Leno M, Conley A J, McKenna P M, Markham P D, Richardson E, Aldrich K, Arora K, Murty L, Carter L, Zolla-Pazner S, Sinangil F
机构信息
Basic Research Laboratory, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892-4255, USA.
出版信息
J Virol. 1998 Dec;72(12):10275-80. doi: 10.1128/JVI.72.12.10275-10280.1998.
Abstract
Vaccine-induced protection of chimpanzees against laboratory-adapted and syncytium-inducing, multiply passaged primary human immunodeficiency virus type 1 (HIV-1) isolates, but not against non-syncytium-inducing, minimally passaged ones, has been demonstrated. Following challenge with such an isolate, HIV-15016, we obtained complete protection in one of three chimpanzees previously protected against low- and high-dose HIV-1SF2 exposures after immunization with an adenovirus-HIV-1MN gp160 priming-HIV-1SF2 gp120 boosting regimen. At challenge, the protected chimpanzee exhibited broad humoral immunity, including neutralizing antibody activity. These results demonstrate the potential of this combination vaccine strategy and suggest that vaccine protection against an HIV isolate relevant to infection of people is feasible.
摘要
疫苗诱导的针对实验室适应的、诱导合胞体的、多次传代的1型人类免疫缺陷病毒（HIV-1）分离株的黑猩猩保护作用已得到证实，但对非诱导合胞体的、传代极少的分离株则无保护作用。在用这样一种分离株HIV-15016进行攻击后，我们在三只先前经腺病毒-HIV-1MN gp160初免-HIV-1SF2 gp120加强免疫方案免疫后对低剂量和高剂量HIV-1SF2暴露有保护作用的黑猩猩中的一只身上获得了完全保护。在攻击时，受保护的黑猩猩表现出广泛的体液免疫，包括中和抗体活性。这些结果证明了这种联合疫苗策略的潜力，并表明针对与人类感染相关的HIV分离株的疫苗保护是可行的。
相似文献
1
Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus.针对一种异源、非诱导合胞体的原发性人类免疫缺陷病毒的疫苗保护作用。
J Virol. 1998 Dec;72(12):10275-80. doi: 10.1128/JVI.72.12.10275-10280.1998.
2
Vaccination of rhesus macaques with recombinant Mycobacterium bovis bacillus Calmette-Guérin Env V3 elicits neutralizing antibody-mediated protection against simian-human immunodeficiency virus with a homologous but not a heterologous V3 motif.用重组卡介苗（Mycobacterium bovis bacillus Calmette-Guérin）Env V3免疫恒河猴，可引发中和抗体介导的针对猿猴-人类免疫缺陷病毒的保护作用，该保护作用针对具有同源而非异源V3基序的病毒。
J Virol. 2005 Feb;79(3):1452-62. doi: 10.1128/JVI.79.3.1452-1462.2005.
3
Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization.通过免疫接种实现对黑猩猩的长期保护，使其免受高剂量HIV-1攻击。
Nat Med. 1997 Jun;3(6):651-8. doi: 10.1038/nm0697-651.
4
Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1.用MN-rgp120免疫的黑猩猩对人免疫缺陷病毒1型原代分离株的异源感染具有保护作用。
J Infect Dis. 1996 Jan;173(1):52-9. doi: 10.1093/infdis/173.1.52.
5
Polyvalent envelope glycoprotein vaccine elicits a broader neutralizing antibody response but is unable to provide sterilizing protection against heterologous Simian/human immunodeficiency virus infection in pigtailed macaques.多价包膜糖蛋白疫苗可引发更广泛的中和抗体反应，但无法为猪尾猕猴提供针对异源猴/人免疫缺陷病毒感染的无菌保护。
J Virol. 2001 Mar;75(5):2224-34. doi: 10.1128/JVI.75.5.2224-2234.2001.
6
An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains.一种基于腺病毒的HIV B亚型初免/加强疫苗方案可引发介导针对非B亚型HIV毒株的广泛抗体依赖性细胞毒性的抗体。
J Acquir Immune Defic Syndr. 2006 Nov 1;43(3):270-7. doi: 10.1097/01.qai.0000230318.40170.60.
7
Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees.采用初免-加强疫苗方案在黑猩猩中诱导针对T细胞系适应株和原发性人类免疫缺陷病毒1型分离株的中和抗体。
J Virol. 1998 Feb;72(2):1052-9. doi: 10.1128/JVI.72.2.1052-1059.1998.
8
Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies.1型人类免疫缺陷病毒ADA株gp120单体与gp140三聚体作为诱导中和抗体免疫原的比较
AIDS Res Hum Retroviruses. 2005 Jan;21(1):58-67. doi: 10.1089/aid.2005.21.58.
9
HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees.HIV-1包膜诱导的中和抗体滴度与黑猩猩的保护作用及病毒载量相关。
Vaccine. 1994 Sep;12(12):1141-8. doi: 10.1016/0264-410x(94)90185-6.
10
Immunogenicity of recombinant adenovirus-human immunodeficiency virus vaccines in chimpanzees following intranasal administration.重组腺病毒-人类免疫缺陷病毒疫苗经鼻内给药后在黑猩猩体内的免疫原性。
AIDS Res Hum Retroviruses. 1994 Nov;10(11):1443-9. doi: 10.1089/aid.1994.10.1443.
引用本文的文献
1
The immunological impact of adenovirus early genes on vaccine-induced responses in mice and nonhuman primates.腺病毒早期基因对小鼠和非人灵长类动物疫苗诱导反应的免疫影响。
J Virol. 2021 Mar 10;95(7). doi: 10.1128/JVI.02253-20. Epub 2021 Jan 13.
2
Genetic Adjuvants in Replicating Single-Cycle Adenovirus Vectors Amplify Systemic and Mucosal Immune Responses against HIV-1 Envelope.复制型单周期腺病毒载体中的遗传佐剂可增强针对HIV-1包膜的全身和黏膜免疫反应。
Vaccines (Basel). 2020 Feb 2;8(1):64. doi: 10.3390/vaccines8010064.
3
Beyond Oncolytics: E1B55K-Deleted Adenovirus as a Vaccine Delivery Vector.超越溶瘤作用：缺失E1B55K的腺病毒作为疫苗递送载体
PLoS One. 2016 Jul 8;11(7):e0158505. doi: 10.1371/journal.pone.0158505. eCollection 2016.
4
HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaques.HIV-1 CD4 诱导的（CD4i）gp120 表位疫苗可促进 B 和 T 细胞的反应，从而有助于降低恒河猴的病毒载量。
Virology. 2014 Dec;471-473:81-92. doi: 10.1016/j.virol.2014.10.001. Epub 2014 Oct 28.
5
Effects of the deletion of early region 4 (E4) open reading frame 1 (orf1), orf1-2, orf1-3 and orf1-4 on virus-host cell interaction, transgene expression, and immunogenicity of replicating adenovirus HIV vaccine vectors.缺失早期区域 4（E4）开放阅读框 1（orf1）、orf1-2、orf1-3 和 orf1-4 对复制型腺病毒 HIV 疫苗载体病毒-宿主细胞相互作用、转基因表达和免疫原性的影响。
PLoS One. 2013 Oct 15;8(10):e76344. doi: 10.1371/journal.pone.0076344. eCollection 2013.
6
Induction of mucosal HIV-specific B and T cell responses after oral immunization with live coxsackievirus B4 recombinants.口服柯萨奇病毒 B4 重组体诱导黏膜 HIV 特异性 B 和 T 细胞应答。
Vaccine. 2012 May 21;30(24):3666-74. doi: 10.1016/j.vaccine.2012.03.034. Epub 2012 Mar 29.
7
Replicating adenovirus-simian immunodeficiency virus (SIV) recombinant priming and envelope protein boosting elicits localized, mucosal IgA immunity in rhesus macaques correlated with delayed acquisition following a repeated low-dose rectal SIV(mac251) challenge.复制型腺病毒-猴免疫缺陷病毒（SIV）重组疫苗初免和包膜蛋白加强免疫可引起恒河猴局部黏膜 IgA 免疫，与重复低剂量直肠 SIV（mac251）攻击后的延迟获得相关。
J Virol. 2012 Apr;86(8):4644-57. doi: 10.1128/JVI.06812-11. Epub 2012 Feb 15.
8
Genomic analysis reveals pre- and postchallenge differences in a rhesus macaque AIDS vaccine trial: insights into mechanisms of vaccine efficacy.基因组分析揭示恒河猴艾滋病疫苗试验中挑战前后的差异：对疫苗疗效机制的深入了解。
J Virol. 2011 Jan;85(2):1099-116. doi: 10.1128/JVI.01522-10. Epub 2010 Nov 10.
9
Protection against Mucosal SHIV Challenge by Peptide and Helper-Dependent Adenovirus Vaccines.肽和辅助依赖型腺病毒疫苗对黏膜SHIV攻击的保护作用。
Viruses. 2009 Dec 1;1(3):920. doi: 10.3390/v1030920.
10
Enhanced induction of intestinal cellular immunity by oral priming with enteric adenovirus 41 vectors.用肠道腺病毒41型载体进行口服致敏增强肠道细胞免疫诱导
J Virol. 2009 Jan;83(2):748-56. doi: 10.1128/JVI.01811-08. Epub 2008 Nov 5.
本文引用的文献
1
CD8+ lymphocyte antiviral activity in monkeys immunized with SIV recombinant poxvirus vaccines: potential role in vaccine efficacy.用SIV重组痘病毒疫苗免疫的猴子中CD8 +淋巴细胞的抗病毒活性：在疫苗效力中的潜在作用
AIDS Res Hum Retroviruses. 1999 Mar 20;15(5):461-70. doi: 10.1089/088922299311213.
2
Generation of CD8 suppressor factor and beta chemokines, induced by xenogeneic immunization, in the prevention of simian immunodeficiency virus infection in macaques.异种免疫诱导产生的CD8抑制因子和β趋化因子在预防猕猴感染猿猴免疫缺陷病毒中的作用
Proc Natl Acad Sci U S A. 1998 Apr 28;95(9):5223-8. doi: 10.1073/pnas.95.9.5223.
3
Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees.采用初免-加强疫苗方案在黑猩猩中诱导针对T细胞系适应株和原发性人类免疫缺陷病毒1型分离株的中和抗体。
J Virol. 1998 Feb;72(2):1052-9. doi: 10.1128/JVI.72.2.1052-1059.1998.
4
An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge.一种腺病毒-猴免疫缺陷病毒包膜疫苗可在恒河猴中引发体液免疫、细胞免疫和黏膜免疫反应，并在阴道攻毒后降低病毒载量。
J Virol. 1997 Nov;71(11):8531-41. doi: 10.1128/JVI.71.11.8531-8541.1997.
5
Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization.通过免疫接种实现对黑猩猩的长期保护，使其免受高剂量HIV-1攻击。
Nat Med. 1997 Jun;3(6):651-8. doi: 10.1038/nm0697-651.
6
Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination.通过DNA疫苗接种保护黑猩猩免受高剂量异源HIV-1攻击。
Nat Med. 1997 May;3(5):526-32. doi: 10.1038/nm0597-526.
7
Human immunodeficiency virus type 1 neutralizing antibody serotyping using serum pools and an infectivity reduction assay.使用血清库和感染性降低试验进行1型人类免疫缺陷病毒中和抗体血清分型
AIDS Res Hum Retroviruses. 1996 Sep 20;12(14):1319-28. doi: 10.1089/aid.1996.12.1319.
8
9
Recombinant subunit vaccines as an approach to study correlates of protection against primate lentivirus infection.重组亚单位疫苗作为一种研究针对灵长类慢病毒感染的保护性相关因素的方法。
Immunol Lett. 1996 Jun;51(1-2):115-9. doi: 10.1016/0165-2478(96)02564-3.
10
The consequence of passive administration of an anti-human immunodeficiency virus type 1 neutralizing monoclonal antibody before challenge of chimpanzees with a primary virus isolate.在黑猩猩用一种原发性病毒分离株攻击之前被动给予抗1型人类免疫缺陷病毒中和单克隆抗体的后果。
J Virol. 1996 Oct;70(10):6751-8. doi: 10.1128/JVI.70.10.6751-6758.1996.
Zotero 插件